GlassScriptPhysician profile
John R Favetta
NPI 1497861090
$53,736.73
in general payments reported to CMS, 2019-2025
25 companies · $544 in 2025
The $544 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $8,725 · 2021: $12K · 2022: $7,826 · 2023: $745 · 2024: $960 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,213 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,212.63 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $30,020.90 | 2019-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $14,588.69 | 2019-2022 | |
| Dompe US, INC. | $3,433.24 | 2019-2023 | Oxervate |
| Eyevance Pharmaceuticals LLC | $1,652.81 | 2019-2023 | Flarex |
| Aerie Pharmaceuticals, INC. | $639.55 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $588.26 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Oyster Point Pharma, INC. | $411.33 | 2022-2025 | Tyrvaya, Ryzumvi |
| Biotissue Holdings INC. | $376.92 | 2021-2025 | |
| Allergan, INC. | $332.42 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $283.24 | 2019-2021 | |
| Glaukos Corporation | $243.72 | 2019-2021 | |
| Harrow Eye, LLC | $189.27 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $184.30 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $169.80 | 2019-2023 | |
| Alcon Vision LLC | $135.73 | 2022-2025 | Rocklatan, Eysuvis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $101.15 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Mallinckrodt Hospital Products INC. | $78.58 | 2022-2024 | Acthar |
| Genentech USA, INC. | $69.21 | 2019 | |
| Shire North American Group INC | $56.66 | 2019 | |
| Ocular Therapeutix, INC. | $54.92 | 2022-2023 | Dextenza |
| Abbvie INC. | $48.70 | 2022-2025 | |
| Thea Pharma INC. | $24.66 | 2024 | Iyuzeh |
| Akorn, INC. | $24.55 | 2019-2020 | |
| Horizon Therapeutics Plc | $14.55 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $13.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Favetta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.